# US 11,439,745 B2 · Drug delivery device > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 11,439,745 B2 - Document ID: US11439745B2 - Status: Granted - Kind: B2 - Application number: 16/779,135 - Filed: 2020-01-31 - Published: 2020-06-11 - Granted: 2022-09-13 - Earliest claimed: 2012-11-21 - Assignees: Amgen Inc. - Applicants: Amgen Inc. - Inventors: Lawrence Ring; Dhairya Mehta; Stephanie Toy; Ferry Tamtoro; Alexander Stuart Cairns; Scott R. Gibson - Web page: https://patentgrep.com/patent/US11439745B2 ## CPC - A61M 5/14248: {of the skin patch type} - A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)} - A61K 38/193: {Colony stimulating factors [CSF]} - A61K 38/26: Glucagons - A61K 38/28: Insulins - A61M 5/14: Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor - A61M 5/14216: {Reciprocating piston type} - A61M 5/158: Needles {for infusions; Accessories therefor, e.g. for inserting infusion needles, or for holding them on the body} - A61M 5/20: Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically (A61M5/142 takes precedence) - A61M 5/3134: {characterised by constructional features of the distal end, i.e. end closest to the tip of the needle cannula} - A61M 5/3286: {Needle tip design, e.g. for improved penetration} - A61M 5/3287: {Accessories for bringing the needle into the body; Automatic needle insertion (A61M5/20, A61M5/31525 take precedence)} - A61M 5/3291: {Shafts with additional lateral openings} - A61M 5/422: {Desensitising skin} - A61M 25/0015: {Making lateral openings in a catheter tube, e.g. holes, slits, ports, piercings of guidewire ports; Methods for processing the holes, e.g. smoothing the edges} - A61M 25/0068: {Static characteristics of the catheter tip, e.g. shape, atraumatic tip, curved tip or tip structure} - A61M 25/007: {Side holes, e.g. their profiles or arrangements; Provisions to keep side holes unblocked} - A61M 25/02: Holding devices, e.g. on the body - C07K 14/535: Granulocyte CSF; Granulocyte-macrophage CSF - C12N 9/6424: {Serine endopeptidases (3.4.21)} - A61M 2005/1401: {Functional features} - A61M 2005/1585: {Needle inserters} - A61M 2005/3022: {Worn on the body, e.g. as patches (pressure infusion of the skin patch type A61M5/14248)} - A61M 2005/3289: {with rotation of the needle, e.g. to ease penetration} - A61M 2025/0073: {Tip designed for influencing the flow or the flow velocity of the fluid, e.g. inserts for twisted or vortex flow} - A61M 2202/0007: introduced into the body - A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)} - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00) ## Abstract A drug delivery device includes a blunt cannula and a reservoir. The blunt cannula has a cylindrical wall that defines an axial passage between a first end and a second end of the blunt cannula. The wall has at least a first tapered region at the first end to define an opening in fluid communication with the axial passage and adapted at the first end to resist interruption of fluid flow through the axial passage and out of the first end of the blunt cannula. The reservoir is connected to the second end of the blunt cannula. ## Claims ### Claim 1 A wearable drug delivery device comprising: a housing having an opening; an adhesive disposed on a surface of the housing for attaching the housing to skin of a patient; a blunt cannula moveable relative to the housing and having a wall that defines a passage between a first end and a second end of the blunt cannula, the wall having at least a first tapered region at the first end to define an opening in fluid communication with the passage, and at least one side port formed in the wall to resist interruption of fluid flow through the passage and out of the first end of the blunt cannula; a reservoir disposed in the housing and configured to be in fluid communication with the second end of the blunt cannula at least during drug delivery; a plunger disposed in the reservoir; a needle, wherein the second end of the blunt cannula is configured to be operably connected in fluid communication with the reservoir via the needle to deliver the drug to a patient; and wherein the blunt cannula is initially retracted within the housing and subsequently deployed in a linear direction through the opening in the housing for insertion into the patient, and wherein at least a portion of an element disposed at and/or coupled with the second end of the cannula surrounds at least a portion of the needle. ### Claim 2 (depends on 1) The wearable drug delivery device of claim 1, wherein the element comprises a hub surrounding the at least a portion of the needle. ### Claim 3 (depends on 2) The wearable drug delivery device of claim 2, wherein the hub has a larger diameter than the second end of the blunt cannula. ### Claim 4 (depends on 1) The wearable drug delivery device of claim 1, wherein the needle has a first end and a second end, the second end being connected to the reservoir. ### Claim 5 (depends on 4) The wearable drug delivery device of claim 4, wherein the blunt cannula is initially retracted within the housing in a storage state, and the second end of the needle is connected to the reservoir in the storage state. ### Claim 6 (depends on 1) The wearable drug delivery device of claim 1, wherein the at least one side port is within the first tapered region of the blunt cannula. ### Claim 7 (depends on 1) The wearable drug delivery device of claim 1, wherein the at least one side port comprises a pair of side ports. ### Claim 8 (depends on 7) The wearable drug delivery device of claim 7, wherein the pair of side ports are aligned with each other across the passage of the blunt cannula. ### Claim 9 (depends on 1) The wearable drug delivery device of claim 1, wherein the opening in the housing extends through the surface of the housing. ### Claim 10 (depends on 1) The wearable drug delivery device of claim 1, comprising an introducer needle disposed in the blunt cannula and adapted to protrude outwardly from the opening in the first end of the blunt cannula for introducing the blunt cannula into skin of the patient and subsequently retract into the opening in the first end of the blunt cannula prior to drug delivery. ### Claim 11 (depends on 1) The wearable drug delivery device of claim 1, wherein the blunt cannula is configured to move through the opening in the housing for insertion into the patient. ### Claim 12 (depends on 1) The wearable drug delivery device of claim 1, wherein the needle is free from contact with the patient during insertion of the blunt cannula into the patient. ### Claim 13 A wearable drug delivery device comprising: a housing having an opening; an adhesive disposed on a surface of the housing for attaching the housing to skin of a patient; a reservoir disposed in the housing and adapted to contain a drug; a plunger disposed in the reservoir; a first needle; a fluid conduit; a hub distinct from the reservoir and surrounding at least a portion of the first needle, wherein the hub is coupled to the fluid conduit; a delivery member having a wall that defines a passage between a first end and a second end of the delivery member, the first end of the delivery member being initially retracted within the housing and subsequently deployed through the opening in the housing for introduction into the skin of the patient, the second end of the delivery member configured to be operably connected in fluid communication with the reservoir via at least the first needle and the fluid conduit; a septum, wherein the first needle is configured to pierce the septum to facilitate fluid communication between the reservoir and the delivery member; wherein the first end of the delivery member is configured to move through the opening in the housing for introduction into the skin of the patient; and wherein the drug delivery device is free of an introducer needle for introducing the delivery member into the patient. ### Claim 14 (depends on 13) The wearable drug delivery device of claim 13, wherein the delivery member comprises a second needle. ### Claim 15 (depends on 13) The wearable drug delivery device of claim 13, comprising at least one side port in the wall of the delivery member at the first end of the delivery member. ### Claim 16 (depends on 15) The wearable drug delivery device of claim 15, wherein the at least one side port comprises a pair of side ports. ### Claim 17 (depends on 13) The wearable drug delivery device of claim 13, wherein the first needle is free from contact with the patient during introduction of the delivery member into the skin of the patient. ### Claim 18 (depends on 13) The wearable drug delivery device of claim 13, wherein the hub is directly coupled to the fluid conduit. ### Claim 19 (depends on 18) The wearable drug delivery device of claim 18, wherein the hub is disposed upstream of the fluid conduit. ### Claim 20 A wearable drug delivery device comprising: a housing having an opening; an adhesive disposed on a surface of the housing for attaching the housing to skin of a patient; a blunt cannula moveable relative to the housing and having a wall that defines a passage between a first end and a second end of the blunt cannula, the wall having at least a first tapered region at the first end to define an opening in fluid communication with the passage, and at least one side port formed in the wall to resist interruption of fluid flow through the passage and out of the first end of the blunt cannula; a reservoir disposed in the housing and configured to be in fluid communication with the second end of the blunt cannula at least during drug delivery; a plunger disposed in the reservoir; a needle, wherein the second end of the blunt cannula is configured to be operably connected in fluid communication with the reservoir via the needle to deliver the drug to a patient; a hub surrounding at least a portion of the needle, wherein the hub is disposed at the second end of the blunt cannula; and wherein the blunt cannula is initially retracted within the housing and subsequently deployed in a linear direction through the opening in the housing for insertion into the patient, and wherein the needle is free from contact with the patient during insertion of the blunt cannula into the patient.